Most Recent
US drug company Allergan is facing a class action on behalf of women implanted with textured breast implants that were recalled after they were linked to a form of non-Hodgkin lymphoma.
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
AI tech company Paige can't patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.
The law firm running a class action against Exactech over allegedly faulty joint implants is facing the "impossible task" of settling the case by January, the "drop dead" deadline for resolving the claim under its US parent company's restructuring.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
A commission baked into a funding agreement in a class action against Mayne Pharma is under threat, with a judge mulling an order off his own bat to cut the rate.
Australian Clinical Labs may seek to strike out part of the OAIC's case over a 2022 data breach, arguing it would unfairly allow the watchdog to allege both single and multiple contraventions of privacy law.